Your session is about to expire
← Back to Search
New Imaging Technique for Pancreatic Cancer
Study Summary
This trial is testing a new imaging agent to see if it can better detect pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 10 Patients • NCT03801915Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had a severe allergic reaction to a specific type of medication made from human or humanized antibodies.My CA19-9 levels are above normal, or my biopsy was CA19-9 positive.I have a tumor that is at least 2 cm large, visible on CT or MRI.I am scheduled for surgery or biopsy for my pancreatic cancer as part of my standard treatment.My cancer is advanced pancreatic or CA19-9 positive.I am recommended for surgery or biopsy for my IPMN condition.I am not on any cancer treatment except MVT-5873.I can care for myself and am up and about more than 50% of my waking hours.My team of doctors, including a surgeon and radiologist, agree surgery is needed for suspected pancreatic cancer.Your blood counts, liver and kidney function must be within certain limits.My pancreatic cancer is confirmed or highly suspected to be at stage T2 or T3.My pancreatic cancer is confirmed or highly suspected and is at an intermediate stage.I am scheduled for surgery for my pancreatic cancer or IPMN.I have not had major surgery in the last 4 weeks.I am 18 years old or older.I have been diagnosed with HIV.I do not have any ongoing serious infections requiring treatment.
- Group 1: 89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current enrollment quota for this research project?
"Affirmative. Clinicaltrials.gov displays information that this medical trial is actively seeking participants - it was posted on May 10th 2021 and last updated on 3rd May 2022. The research calls for 15 volunteers from 7 locations to take part in the study."
Are there a number of sites conducting this investigation in the same state?
"Currently, Memorial Sloan Kettering Westchester (Consent only) in Harrison, Memorial Sloan Kettering Bergen (Consent only ) in Montvale, and Memorial Sloan Kettering Nassau (Consent Only) in Uniondale are the three primary locations for recruitment into this trial. There are also 7 other sites that are accepting patients as well."
Has MVT-5873 met the standards for governmental authorization?
"Our team at Power gave MVT-5873 a rating of 1 due to the limited clinical data available relating to safety and efficacy associated with this Phase 1 trial."
Is the enrollment period of this clinical trial still ongoing?
"According to data found on clinicaltrials.gov, this research is presently accepting applicants - it was initially posted on May 10th 2021 and recently updated on May 3rd 2022."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger